pep-05049 v1 CC-BY-SA-4.0
Vasopressin metabolic peptide
An experimental peptide aimed at the same body target as weight-loss drugs like Ozempic, being studied for possible effects on blood sugar and metabolism; not an approved medicine.
status
Someone proposed this peptide.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
A computer predicted how the peptide binds to its target.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
Someone else ran the same prediction and got the same result.
A second contributor repeated the computation on their own hardware and the scores matched.
The peptide was actually made in a lab.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
The peptide was tested on its target in a lab.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
prediction metrics
ipTM0.561
pTM0.701
avg pLDDT42.7
ranking score0.690
STRUCTURE · PEP-05049 × GLP-1R
ranking0.690
target interface 4.5Å peptide drag rotate · ctrl+scroll zoom · right-click pan
sequence
1510152025303539
ASDRSNATQLDGP AGALLLRLVQLAG APEPFEPAQPDAY
in the news
details
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.5605124235153198 | openfold3-mlx |
| ranking score | 0.6902785301208496 | openfold3-mlx |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.925 | global PDE — lower = better |
| disorder | 0.203 | fraction disordered |
| chain pair ipTM (A, B) | 0.561 | interface quality |
▸3-letter notation
Ala-Ser-Asp-Arg-Ser-Asn-Ala-Thr-Gln-Leu-Asp-Gly-Pro-Ala-Gly-Ala-Leu-Leu-Leu-Arg-Leu-Val-Gln-Leu-Ala-Gly-Ala-Pro-Glu-Pro-Phe-Glu-Pro-Ala-Gln-Pro-Asp-Ala-Tyr
▸recipeopenfold3-mlx 0.3.1
| parameter | value |
|---|---|
| model | openfold3-mlx 0.3.1 |
| weights | — |
| hardware | — |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | — |
| diffusion samples | 1 |
| runtime | 446s |
| predicted by | mlx@peptide |
| predicted at | 2026-04-14 |
▸citationbibtex
peptidemodel (2026). Vasopressin metabolic peptide (pep-05049, v1). PeptideModel. https://peptidemodel.com/card/pep-05049
@peptide{pep05049,
sequence = {ASDRSNATQLDGPAGALLLRLVQLAGAPEPFEPAQPDAY},
target = {glp-1r},
author = {peptidemodel},
year = {2026},
status = {computed}
} related peptides
references
discussion
sign in to comment